Device Structural Heart

Tendyne

Payments companies reported to CMS as associated with Tendyne. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$168Kassociated payments (2023-2025)
98clinicians with associated payments
1company reporting

By year

2025 $168K

Payments reported as associated with Tendyne, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Thoracic Surgery (Cardiothoracic Vascular Surgery) $97K
Interventional Cardiology $35K
Cardiovascular Disease $15K
Surgery $13K
Vascular Surgery $2,205
Neurology (Psychiatry & Neurology) $1,781

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Tendyne

These are the largest totals companies reported as associated with Tendyne. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Benjamin Sun Minneapolis, MN Thoracic Surgery (Cardiothoracic Vascular Surgery) $30,963.99
Bassam Shukrallah Little Rock, AR Thoracic Surgery (Cardiothoracic Vascular Surgery) $26,761.18
Andy Kiser Pittsburgh, PA Surgery $9,625.00
Faraz Kerendi Austin, TX Thoracic Surgery (Cardiothoracic Vascular Surgery) $6,866.18
Michael Rinaldi Charlotte, NC Cardiovascular Disease $4,875.00
Frederick St Goar Mountain View, CA Interventional Cardiology $4,759.02
Suzanne Baron Boston, MA Interventional Cardiology $4,550.00
Vinod Thourani Marietta, GA Thoracic Surgery (Cardiothoracic Vascular Surgery) $4,470.00
Jeremy Robbins Boston, MA Cardiovascular Disease $4,225.00
Paul Sorajja Phoenix, AZ Interventional Cardiology $3,106.21

Prescribed Tendyne?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.